收费全文 | 396466篇 |
免费 | 37674篇 |
国内免费 | 22520篇 |
医药卫生 | 456660篇 |
2024年 | 1773篇 |
2023年 | 5278篇 |
2022年 | 13382篇 |
2021年 | 16902篇 |
2020年 | 14056篇 |
2019年 | 9144篇 |
2018年 | 9723篇 |
2017年 | 11400篇 |
2016年 | 9518篇 |
2015年 | 15661篇 |
2014年 | 20418篇 |
2013年 | 23668篇 |
2012年 | 33818篇 |
2011年 | 35809篇 |
2010年 | 30271篇 |
2009年 | 26878篇 |
2008年 | 28542篇 |
2007年 | 27592篇 |
2006年 | 24828篇 |
2005年 | 20761篇 |
2004年 | 14801篇 |
2003年 | 12730篇 |
2002年 | 10106篇 |
2001年 | 8984篇 |
2000年 | 7314篇 |
1999年 | 4128篇 |
1998年 | 1987篇 |
1997年 | 2057篇 |
1996年 | 1538篇 |
1995年 | 1443篇 |
1994年 | 1328篇 |
1993年 | 916篇 |
1992年 | 1099篇 |
1991年 | 961篇 |
1990年 | 883篇 |
1989年 | 782篇 |
1988年 | 704篇 |
1987年 | 626篇 |
1986年 | 588篇 |
1985年 | 478篇 |
1984年 | 407篇 |
1983年 | 335篇 |
1982年 | 310篇 |
1981年 | 229篇 |
1980年 | 200篇 |
1979年 | 201篇 |
1978年 | 193篇 |
1977年 | 215篇 |
1976年 | 194篇 |
1974年 | 156篇 |
Methods: This is a retrospective analysis of discharge records from the National Inpatient Sample database for patients receiving allo-HSCT between 1 January 2009 and 31 December 2013. Allo-HSCT discharges with an aGVHD diagnosis were included in the aGVHD group and those without any graft-versus-host disease (GVHD) diagnosis comprised the non-GVHD group. Mortality, LOS and costs were compared between the two groups, as well as within subgroups, including age (<18 vs. ≥18 years) and survival status (alive vs. deceased) at discharge.
Results: Overall, mortality (16.2% vs. 5.3%; p?<?.01), median hospital LOS (42.0 vs. 26.0 days; p?<?.01) and median total costs ($173,144 vs. $98,982; p?<?.01) were significantly increased in patients with aGVHD versus those without GVHD during hospitalizations for allo-HSCT, irrespective of age group. Patients with aGVHD who were <18 years of age had a lower mortality rate but greater hospital LOS and total costs versus patients aged ≥18 years. Patients who died during allo-HSCT hospitalization had longer LOS and incurred greater costs than those who survived in both the aGVHD and non-GVHD groups.
Conclusion: Occurrence of aGVHD during allo-HSCT admissions resulted in a tripling of the mortality rate and a near doubling of hospital LOS and total costs. In addition, death during allo-HSCT hospitalizations was associated with greater healthcare utilization and costs. Effectively mitigating aGVHD may improve survival and substantially reduce hospital LOS and costs for allo-HSCT. 相似文献